STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. Sec-filings
  3. BDRX
  4. [EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 21, 2025
Accession Number: 0001214659-25-016809
Submission Type: POS AM
CIK: 0001643918
Company Name: Biodexa Pharmaceuticals Plc
File Number: 333-272693

Source: View Original Filing on SEC EDGAR

Stock BDRX logo
Biodexa Pharmaceuticals plc

NASDAQ:BDRX

BDRX Rankings

#6748 Ranked by Market Cap
N/A Ranked by Dividends

BDRX Latest News

Nov 24, 2025
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Nov 3, 2025
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Oct 6, 2025
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Sep 12, 2025
Interim results for the six months ended June 30, 2025
Sep 8, 2025
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

BDRX Latest SEC Filings

Nov 24, 2025
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 24, 2025
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 24, 2025
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing
Nov 17, 2025
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing
Nov 17, 2025
[F-1] Biodexa Pharmaceuticals Plc Foreign Issuer IPO Registration

BDRX Stock Data

2.71M
613.62k
0.95%
6.25%
0.69%
Biotechnology
Healthcare
Link
United Kingdom
Cardiff